An Open-Label, Multi-Center Phase II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HRS-6209 in Combination With Fulvestrant or Letrozole in Patients With Solid Tumor
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects with HR-Positive/HER2-Negative solid tumor.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Ability to understand the trial procedures and possible adverse events, voluntarily participate in the trial.
• Adequate bone marrow and other vital organ functions
• Adequate liver function tests
• HR-positive or HER2-negative solid tumor patients
Locations
Other Locations
Australia
Ballarat Base Hospital
RECRUITING
Ballarat
Lyell McEwin Hospital
RECRUITING
Elizabeth Vale
Frankston Hospital
RECRUITING
Frankston
Contact Information
Primary
Kathy You
kathyyou@atridia.com
+61 02 9299 0433
Backup
Ravi Patel
ravi.patel@atridia.com
+61 452 363 506
Time Frame
Start Date: 2026-05-15
Estimated Completion Date: 2027-11-10
Participants
Target number of participants: 15
Treatments
Experimental: HRS-6209 Capsules and fulvestrant injection
Related Therapeutic Areas
Sponsors
Leads: Atridia Pty Ltd.